Guilong Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Guilong Guo has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Huayan Gu
Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University
4 shared publicationsJiaLing Ding
Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University
3 shared publications- Jie-Yu Zhou
Department of Thyroid and Breast Surgery, The Wenzhou Central Hospital, Wenzhou, Zhejiang, 325000, People’s Republic of China
3 shared publications Kangkang Lu
Department of Breast Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
3 shared publicationsQi-Di Huang
Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
3 shared publicationsQidi Huang
Department of Breast Surgery, First Affiliated Hospital of Wenzhou Medical University
3 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1889467
Breast implant-associated anaplastic large cell lymphoma: a case report and literature review
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell non-Hodgkin lymphoma primarily associated with textured breast implants. Its pathological hallmarks include CD30 positivity, ALK negativity, and clonal T-cell receptor gene rearrangement. Complete surgical excision is the primary treatment modality, and early diagnosis combined with standardized management is associated with a favorable prognosis. We report a case of BIA-ALCL in a 47-year-old female who presented with breast swelling 20 years after receiving textured breast implants. To the best of our knowledge, this is the first documented case of BIA-ALCL in mainland China. Preoperative aspiration was not suggestive of BIA-ALCL, and the diagnosis was ultimately confirmed through histopathological examination of the capsule tissue. Based on a comprehensive postoperative systemic evaluation, no adjuvant therapy was required.
- 6 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1889467
Open AccessBreast implant-associated anaplastic large cell lymphoma: a case report and literature review
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell non-Hodgkin lymphoma primarily associated with textured breast implants. Its pathological hallmarks include CD30 positivity, ALK negativity, and clonal T-cell receptor gene rearrangement. Complete surgical excision is the primary treatment modality, and early diagnosis combined with standardized management is associated with a favorable prognosis. We report a case of BIA-ALCL in a 47-year-old female who presented with breast swelling 20 years after receiving textured breast implants. To the best of our knowledge, this is the first documented case of BIA-ALCL in mainland China. Preoperative aspiration was not suggestive of BIA-ALCL, and the diagnosis was ultimately confirmed through histopathological examination of the capsule tissue. Based on a comprehensive postoperative systemic evaluation, no adjuvant therapy was required.
- Open Access
- 1 March 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 441-460
A Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer
Purpose: To explore the efficacy and safety of pyrotinib in a real-world setting in a population with HER2-positive advanced breast cancer, subgroup analysis was conducted based on different clinicopathological features to further explore the general characteristics of patients, tumor nature, and the effect of various lines of treatment before patients started pyrotinib on the efficacy of pyrotinib in the real-world study. Methods: The clinical pathological characteristics, drug efficacy and related adverse reactions of HER2-positive MBC patients treated with pyrotinib in six hospitals in Southeast Zhejiang Province from February 2018 to December 2023 were collected and analyzed retrospectively. Results: A total of 342 patients with HER2-positive MBC were enrolled. The median follow-up time of 42.0 months. The median age of the overall population was 52 years (range from 25– 90 year old). Median progression-free survival in the total population was 10.0 months, the median overall survival was 29.0 months. The (objective response rate, ORR) was 40.35% and the (disease control rate, DCR) was 83.92%. The median progression-free survival (PFS) in the total population was 10.0 months, the median overall survival was 29.0 months. And pyrotinib had better mPFS for advanced first-line treatment than for second-third-line and beyond(14.0 months vs.10.0 months vs.6.0 months, P< 0.001). Multivariate Cox regression analysis showed that ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS. Diarrhea was the most common adverse reaction (ADR) in 205 patients (59.94%), which could be controlled by antidiarrheal drugs. Conclusion: This multicenter study suggested that the use of pyrotinib for HER2 positive MBC had a relatively good efficacy, especially for those who received first-line pyrotinib treatment and those who were sensitive to previous trastuzumab treatment. Patients with brain metastasis and liver metastases also benefit from pyrotinib treatment, especially for patients treated with brain radiotherapy and/or surgery. ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS in HER2 Positive MBC patients treated with pyrotinib. The most common adverse reaction associated with pyrotinib is diarrhea, which can be well controlled through antidiarrheal treatment. Pyrotinib combined with vinorelbine has similar efficacy to pyrotinib combined with capecitabine and has fewer side effects, and can be used as an alternative to capecitabine.
- 1 March 2025
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 17, 441-460
Open AccessA Retrospective Real-World Study of Pyrotinib in HER-2 Positive Advanced Breast Cancer
Purpose: To explore the efficacy and safety of pyrotinib in a real-world setting in a population with HER2-positive advanced breast cancer, subgroup analysis was conducted based on different clinicopathological features to further explore the general characteristics of patients, tumor nature, and the effect of various lines of treatment before patients started pyrotinib on the efficacy of pyrotinib in the real-world study. Methods: The clinical pathological characteristics, drug efficacy and related adverse reactions of HER2-positive MBC patients treated with pyrotinib in six hospitals in Southeast Zhejiang Province from February 2018 to December 2023 were collected and analyzed retrospectively. Results: A total of 342 patients with HER2-positive MBC were enrolled. The median follow-up time of 42.0 months. The median age of the overall population was 52 years (range from 25– 90 year old). Median progression-free survival in the total population was 10.0 months, the median overall survival was 29.0 months. The (objective response rate, ORR) was 40.35% and the (disease control rate, DCR) was 83.92%. The median progression-free survival (PFS) in the total population was 10.0 months, the median overall survival was 29.0 months. And pyrotinib had better mPFS for advanced first-line treatment than for second-third-line and beyond(14.0 months vs.10.0 months vs.6.0 months, P< 0.001). Multivariate Cox regression analysis showed that ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS. Diarrhea was the most common adverse reaction (ADR) in 205 patients (59.94%), which could be controlled by antidiarrheal drugs. Conclusion: This multicenter study suggested that the use of pyrotinib for HER2 positive MBC had a relatively good efficacy, especially for those who received first-line pyrotinib treatment and those who were sensitive to previous trastuzumab treatment. Patients with brain metastasis and liver metastases also benefit from pyrotinib treatment, especially for patients treated with brain radiotherapy and/or surgery. ECOG, HER2 status, brain metastasis, liver metastasis, number of pyrotinib treatment lines, previous lapatinib treatment, combined capecitabine therapy and trastuzumab resistance were independent prognostic factors for PFS in HER2 Positive MBC patients treated with pyrotinib. The most common adverse reaction associated with pyrotinib is diarrhea, which can be well controlled through antidiarrheal treatment. Pyrotinib combined with vinorelbine has similar efficacy to pyrotinib combined with capecitabine and has fewer side effects, and can be used as an alternative to capecitabine.
- Open Access
- 6 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1402300
The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
Purpose: This study efforts to explore the association between sarcopenia, an age-related decline in muscle mass and physical function, and clinical outcomes in women with triple-negative breast cancer (TNBC).Methods and materials: This retrospective study included women diagnosed with TNBC who received breast surgery from December 2012 to December 2018. Skeletal muscle mass index (SMI) is utilized to evaluate sarcopenia, which was quantified by the cross-sectional area of muscle at the twelfth thoracic vertebra (T12). Disease-free survival (DFS) and overall survival (OS) are the endpoints. The association of sarcopenia with DFS and OS was statistically analyzed.Results: The study included 130 women in all, with a median age of 55 years (median follow-up, 53 months). Among them, 78 (58.5%) women had sarcopenia (SMI <28.01). 38 patients (29.2%) died and 49 patients (37.7%) experienced a recurrence of breast cancer throughout the follow-up period. Sarcopenia was demonstrated to be a significant predictive factor for both OS (HR,2.885; 95% CI, 1.349–6.169; p = 0.006) and DFS (HR,3.121; 95% CI, 1.578–6.175; p = 0.001) in the multivariate Cox proportional hazard model. There was no significant correlation seen between body mass index and either DFS (p = 0.156) or OS (P = 0.264). Logistic regression model further revealed that sarcopenia was a prognostic factor that was independently associated with both DFS (p = 0.001) and OS (p = 0.006).Conclusions: Among women with TNBC, sarcopenia is associated with worse clinical outcomes. These patients with high risk might be candidates for individual programmed exercise and diet interventions to optimize survival outcomes.
- 6 February 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1402300
Open AccessThe association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
Purpose: This study efforts to explore the association between sarcopenia, an age-related decline in muscle mass and physical function, and clinical outcomes in women with triple-negative breast cancer (TNBC).Methods and materials: This retrospective study included women diagnosed with TNBC who received breast surgery from December 2012 to December 2018. Skeletal muscle mass index (SMI) is utilized to evaluate sarcopenia, which was quantified by the cross-sectional area of muscle at the twelfth thoracic vertebra (T12). Disease-free survival (DFS) and overall survival (OS) are the endpoints. The association of sarcopenia with DFS and OS was statistically analyzed.Results: The study included 130 women in all, with a median age of 55 years (median follow-up, 53 months). Among them, 78 (58.5%) women had sarcopenia (SMI <28.01). 38 patients (29.2%) died and 49 patients (37.7%) experienced a recurrence of breast cancer throughout the follow-up period. Sarcopenia was demonstrated to be a significant predictive factor for both OS (HR,2.885; 95% CI, 1.349–6.169; p = 0.006) and DFS (HR,3.121; 95% CI, 1.578–6.175; p = 0.001) in the multivariate Cox proportional hazard model. There was no significant correlation seen between body mass index and either DFS (p = 0.156) or OS (P = 0.264). Logistic regression model further revealed that sarcopenia was a prognostic factor that was independently associated with both DFS (p = 0.001) and OS (p = 0.006).Conclusions: Among women with TNBC, sarcopenia is associated with worse clinical outcomes. These patients with high risk might be candidates for individual programmed exercise and diet interventions to optimize survival outcomes.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 201-210
Real-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer
Purpose: This study efforts to explore the association of adverse events (AEs) with efficacy in HER2-positive breast cancer patients treated with TDM1. Methods and Materials: This retrospective study included women diagnosed with HER2+ BC treated with TDM1 from January 2012 to December 2023. Event-free survival (EFS) was the endpoint. Tumour response was assessed by disease control rate (DCR) and objective response rate (ORR). The chi-squared test, analysis of variance (ANOVA), Cox proportional hazards regression and Kaplan-Meier survival analysis was employed to evaluate the association of AEs with tumour efficacy. Results: A total of 48 women with a median age of 52 years (median follow-up 8.4 months) were included in the study. Among them, 33 patients (68.8%) experienced adverse events, including platelet depletion and liver function abnormalities, 3 patients (6.3%) discontinued TDM1 due to severe platelet depletion. The overall objective response rate (ORR) was 25.0% and the disease control rate (DCR) was 43.8%. Using the Chi-squared test, we found a statistically significant difference in ORR and DCR between patients who developed a platelet reduction and those who did not. DCR was significantly higher in patients with liver dysfunction than in those without. ANOVA showed that exposure to hepatic dysfunction and platelet reduction, lines of therapy, and treatment course were associated with EFS. In the Kaplan-Meier survival analysis, both liver dysfunction and platelet reduction were correlated with significantly longer EFS (p=0.033 and p=0.038, respectively). Conclusion: This retrospective study demonstrated that AEs were associated with tumour efficacy in patients with HER2+ BC treated with TDM1.
- 1 February 2025
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 17, 201-210
Open AccessReal-World Analysis of the Efficacy and Adverse Events of T-DM1 in Chinese Patients With HER2-Positive Breast Cancer
Purpose: This study efforts to explore the association of adverse events (AEs) with efficacy in HER2-positive breast cancer patients treated with TDM1. Methods and Materials: This retrospective study included women diagnosed with HER2+ BC treated with TDM1 from January 2012 to December 2023. Event-free survival (EFS) was the endpoint. Tumour response was assessed by disease control rate (DCR) and objective response rate (ORR). The chi-squared test, analysis of variance (ANOVA), Cox proportional hazards regression and Kaplan-Meier survival analysis was employed to evaluate the association of AEs with tumour efficacy. Results: A total of 48 women with a median age of 52 years (median follow-up 8.4 months) were included in the study. Among them, 33 patients (68.8%) experienced adverse events, including platelet depletion and liver function abnormalities, 3 patients (6.3%) discontinued TDM1 due to severe platelet depletion. The overall objective response rate (ORR) was 25.0% and the disease control rate (DCR) was 43.8%. Using the Chi-squared test, we found a statistically significant difference in ORR and DCR between patients who developed a platelet reduction and those who did not. DCR was significantly higher in patients with liver dysfunction than in those without. ANOVA showed that exposure to hepatic dysfunction and platelet reduction, lines of therapy, and treatment course were associated with EFS. In the Kaplan-Meier survival analysis, both liver dysfunction and platelet reduction were correlated with significantly longer EFS (p=0.033 and p=0.038, respectively). Conclusion: This retrospective study demonstrated that AEs were associated with tumour efficacy in patients with HER2+ BC treated with TDM1.
- Open Access
- 22 May 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1370453
Breast metastasis from lung adenocarcinoma: a case report and review of the literature
Lung cancer (LC) is one of the most lethal and most prevalent malignant tumors, and lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. Breast cancer (BC) is the most common cancer worldwide, but metastases to the breast from extramammary neoplasms are rare, especially from the lung. Early diagnosis and differentiation of primary from metastatic breast carcinoma are essential. Here, we present a case of metastases to the breast from lung adenocarcinoma, the treatment options varied according to disease progression.
- 22 May 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1370453
Open AccessBreast metastasis from lung adenocarcinoma: a case report and review of the literature
Lung cancer (LC) is one of the most lethal and most prevalent malignant tumors, and lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. Breast cancer (BC) is the most common cancer worldwide, but metastases to the breast from extramammary neoplasms are rare, especially from the lung. Early diagnosis and differentiation of primary from metastatic breast carcinoma are essential. Here, we present a case of metastases to the breast from lung adenocarcinoma, the treatment options varied according to disease progression.
- 14 March 2023
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (6) , 431-442
LncRNA PRKCQ‐AS1 regulates paclitaxel resistance in triple‐negative breast cancer cells through miR‐361‐5p/PIK3C3 mediated autophagy
Paclitaxel (PTX) resistance is a key cause of chemotherapy failure in patients with triple negative breast cancer (TNBC). The aim of this study is to investigate the effect and mechanism of long non‐coding RNA (lncRNA) on the PTX resistance of TNBC cells through autophagy. MDA‐MB‐231 cells are used to induce the PTX‐resistant TNBC cell line MDA‐MB‐231.PR (MDR) by increasing dose intermittently. Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to validate the mRNA levels of phosphoinositide‐3‐kinase class 3 (PIK3C3), miR‐361‐5p and lncRNA PRKCQ‐AS1 in the cells, and Western blot analysis was used to detect the protein expressions of PIK3C3, autophagy‐related, drug‐resistant and apoptosis‐related genes. MDC staining detected the formation of autophagic vacuoles. The interactions between miR‐361‐5p and PIK3C3 and between lncRNA PRKCQ‐AS1 and miR‐361‐5p were verified by dual‐luciferase assay. Cell viability, apoptosis, migration and invasion were assessed by performing MTT, flow cytometry assay, and transwell assay. The mRNA level of miR‐361‐5p and the autophagy and drug resistance levels of TNBC PTX‐resistant cells were significantly up‐regulated. miR‐361‐5p could target autophagy‐related gene PIK3C3, and overexpression of miR‐361‐5p could down‐regulate PIK3C3 protein expression and autophagy level and PTX resistance of MDR cells. LncRNA PRKCQ‐AS1 was selected through bioanalysis, and miR‐361‐5p could target lncRNA PRKCQ‐AS1. In addition, lncRNA PRKCQ‐AS1 level was up‐regulated in TNBC PTX‐resistant cells, and knockdown of lncRNA PRKCQ‐AS1 could weaken autophagy and drug resistance level and could promote cell apoptosis. Overexpression of lncRNA PRKCQ‐AS1 reversed the pro‐apoptotic effect and down‐regulation of autophagy and resistance levels was induced by miR‐361‐5p. In vivo experiments were performed to verify the role of lncRNA PRKCQ‐AS1. We demonstrate that down‐regulation of lncRNA PRKCQ‐AS1 weakened PTX resistance and promoted cell apoptosis by miR‐361‐5p/PIK3C3 mediated autophagy.
- 14 March 2023
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 50 (6) , 431-442
LncRNA PRKCQ‐AS1 regulates paclitaxel resistance in triple‐negative breast cancer cells through miR‐361‐5p/PIK3C3 mediated autophagy
Paclitaxel (PTX) resistance is a key cause of chemotherapy failure in patients with triple negative breast cancer (TNBC). The aim of this study is to investigate the effect and mechanism of long non‐coding RNA (lncRNA) on the PTX resistance of TNBC cells through autophagy. MDA‐MB‐231 cells are used to induce the PTX‐resistant TNBC cell line MDA‐MB‐231.PR (MDR) by increasing dose intermittently. Quantitative real‐time polymerase chain reaction (qRT‐PCR) was used to validate the mRNA levels of phosphoinositide‐3‐kinase class 3 (PIK3C3), miR‐361‐5p and lncRNA PRKCQ‐AS1 in the cells, and Western blot analysis was used to detect the protein expressions of PIK3C3, autophagy‐related, drug‐resistant and apoptosis‐related genes. MDC staining detected the formation of autophagic vacuoles. The interactions between miR‐361‐5p and PIK3C3 and between lncRNA PRKCQ‐AS1 and miR‐361‐5p were verified by dual‐luciferase assay. Cell viability, apoptosis, migration and invasion were assessed by performing MTT, flow cytometry assay, and transwell assay. The mRNA level of miR‐361‐5p and the autophagy and drug resistance levels of TNBC PTX‐resistant cells were significantly up‐regulated. miR‐361‐5p could target autophagy‐related gene PIK3C3, and overexpression of miR‐361‐5p could down‐regulate PIK3C3 protein expression and autophagy level and PTX resistance of MDR cells. LncRNA PRKCQ‐AS1 was selected through bioanalysis, and miR‐361‐5p could target lncRNA PRKCQ‐AS1. In addition, lncRNA PRKCQ‐AS1 level was up‐regulated in TNBC PTX‐resistant cells, and knockdown of lncRNA PRKCQ‐AS1 could weaken autophagy and drug resistance level and could promote cell apoptosis. Overexpression of lncRNA PRKCQ‐AS1 reversed the pro‐apoptotic effect and down‐regulation of autophagy and resistance levels was induced by miR‐361‐5p. In vivo experiments were performed to verify the role of lncRNA PRKCQ‐AS1. We demonstrate that down‐regulation of lncRNA PRKCQ‐AS1 weakened PTX resistance and promoted cell apoptosis by miR‐361‐5p/PIK3C3 mediated autophagy.
- Open Access
- 3 October 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 993263
Real-world outcomes for Chinese breast cancer patients with tumor location of central and nipple portion
Background: The association between tumor location and breast cancer prognosis has been controversial. We sought to explore the relationship between tumors located in central and nipple portion (TCNP) and Chinese breast cancer.Patients and methods: A total of 1,427 breast cancer patients were recruited. There were 328 cases of TCNP and 1,099 cases of tumors in the breast peripheral quadrant (TBPQ). The chi-square test was used to compare different variables between TCNP and TBPQ groups. A one-to-one propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of TCNP and TBPQ groups. Kaplan–Meier curves were used for survival analysis of disease-free survival (DFS), breast cancer-specific survival (BCSS) and overall survival (OS). The Cox proportional hazards regression model was applied to identify prognostic risk factors.Results: The median follow-up time was 58 months. Compared to TBPQ, TCNP patients had significantly larger tumor size, more frequent metastasis to lymph nodes (LN) and more proportions of TNM stage II–III. DFS, OS and BCSS rates were markedly lower in the TCNP group as compared to the TBPQ group before and after PSM (all p < 0.05). Multivariate Cox analysis showed that TCNP was an independent prognostic factor for breast cancer. Subgroup analysis indicated that for breast molecular subtypes and TNM stage II-III breast cancer, TCNP were related to worse prognosis. Multivariate logistic regression revealed that TCNP was an independent contributing factor for LN metastasis.Conclusion: In Chinese breast cancer, compared to TBPQ, TCNP is associated with more LN metastasis and poorer prognosis.
- 3 October 2022
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 9, 993263
Open AccessReal-world outcomes for Chinese breast cancer patients with tumor location of central and nipple portion
Background: The association between tumor location and breast cancer prognosis has been controversial. We sought to explore the relationship between tumors located in central and nipple portion (TCNP) and Chinese breast cancer.Patients and methods: A total of 1,427 breast cancer patients were recruited. There were 328 cases of TCNP and 1,099 cases of tumors in the breast peripheral quadrant (TBPQ). The chi-square test was used to compare different variables between TCNP and TBPQ groups. A one-to-one propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of TCNP and TBPQ groups. Kaplan–Meier curves were used for survival analysis of disease-free survival (DFS), breast cancer-specific survival (BCSS) and overall survival (OS). The Cox proportional hazards regression model was applied to identify prognostic risk factors.Results: The median follow-up time was 58 months. Compared to TBPQ, TCNP patients had significantly larger tumor size, more frequent metastasis to lymph nodes (LN) and more proportions of TNM stage II–III. DFS, OS and BCSS rates were markedly lower in the TCNP group as compared to the TBPQ group before and after PSM (all p < 0.05). Multivariate Cox analysis showed that TCNP was an independent prognostic factor for breast cancer. Subgroup analysis indicated that for breast molecular subtypes and TNM stage II-III breast cancer, TCNP were related to worse prognosis. Multivariate logistic regression revealed that TCNP was an independent contributing factor for LN metastasis.Conclusion: In Chinese breast cancer, compared to TBPQ, TCNP is associated with more LN metastasis and poorer prognosis.
- Open Access
- 1 February 2022
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 525-534
Male Breast Carcinoma Metastatic to the Choroid: A Case Report and Opinions of Management
Male breast carcinoma metastatic to the choroid is very rare and often related to poor prognosis. Herein, we report the findings in a Chinese male breast cancer patient who developed choroidal metastasis, and give opinions on systemic treatments. A 45-year-old Chinese male represented with difficulty breathing and visual impairment in the left eye 6 years after his breast cancer surgery and postoperative adjuvant treatment. PET/CT revealed multi-organs metastasis of the patient. The IHC indicated the lung lesion to be originated from the breast (ER+/PR+/HER2-). Eye examination provided evidence for breast cancer choroidal metastasis. Two cycles of TX (docetaxel + capecitabine) followed by two courses of GP (gemcitabine + cis-platinum) were applied as salvage chemotherapy. Metastases in his lung and bone remained stable. As for choroidal metastasis, a regimen of CDK4/6 inhibitor (Palbociclib) plus fulvestrant was recommended to the patient, which led to a good response. Notably, CDK4/6 inhibitor combined with endocrine therapy may be considered as an effective treatment for hormonal receptor-positive breast cancer patients with choroidal metastasis. We recommend that eye examination should not be neglected in breast cancer patients.
- 1 February 2022
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 525-534
Open AccessMale Breast Carcinoma Metastatic to the Choroid: A Case Report and Opinions of Management
Male breast carcinoma metastatic to the choroid is very rare and often related to poor prognosis. Herein, we report the findings in a Chinese male breast cancer patient who developed choroidal metastasis, and give opinions on systemic treatments. A 45-year-old Chinese male represented with difficulty breathing and visual impairment in the left eye 6 years after his breast cancer surgery and postoperative adjuvant treatment. PET/CT revealed multi-organs metastasis of the patient. The IHC indicated the lung lesion to be originated from the breast (ER+/PR+/HER2-). Eye examination provided evidence for breast cancer choroidal metastasis. Two cycles of TX (docetaxel + capecitabine) followed by two courses of GP (gemcitabine + cis-platinum) were applied as salvage chemotherapy. Metastases in his lung and bone remained stable. As for choroidal metastasis, a regimen of CDK4/6 inhibitor (Palbociclib) plus fulvestrant was recommended to the patient, which led to a good response. Notably, CDK4/6 inhibitor combined with endocrine therapy may be considered as an effective treatment for hormonal receptor-positive breast cancer patients with choroidal metastasis. We recommend that eye examination should not be neglected in breast cancer patients.
- 27 October 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (36) , 5077-5091
Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer
Background: Triple-negative breast cancer (TNBC) is an aggressive disease. Nomograms can predict prognosis of patients with TNBC. Methods: A total of 745 eligible TNBC patients were recruited and r...
- 27 October 2021
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (36) , 5077-5091
Development of prognostic nomograms using institutional data for patients with triple-negative breast cancer
Background: Triple-negative breast cancer (TNBC) is an aggressive disease. Nomograms can predict prognosis of patients with TNBC. Methods: A total of 745 eligible TNBC patients were recruited and r...
- Open Access
- 14 April 2021
- Published by Springer Nature in Research Square
Malignant Phyllodes Tumor With Metastases to the Femur the Lung and Bilateral Axillas: A Case Report and Review of Literature
Background: Phyllodes tumor is rare accounting for Case presentation: This case report presents a 34-year-old woman suffered from metastases to the femur the lung and bilateral axillas from a malignant phyllodes tumor in 9 years. The most recent recurrence was discovered on bilateral axillas. The patient accepted adjuvant chemotherapy. However, because no obvious benefit of chemotherapy was found, the patient received bilateral axillary lymph node dissection finally. Genetic testing after surgery showed tumor-specific mutations and mutations about thepolymorphism of drug metabolism-related enzymes. Conclusions: The primary treatment modality for phyllodes tumor is surgery. For metastases, adjuvant chemotherapy may be efficient. However, when the effect of chemotherapy is not obvious, aggressive surgical therapies should be performed. Besides, genetic testing can provide advices on effective treatments.
- 14 April 2021
- Published by Springer Nature in Research Square
Open AccessMalignant Phyllodes Tumor With Metastases to the Femur the Lung and Bilateral Axillas: A Case Report and Review of Literature
Background: Phyllodes tumor is rare accounting for Case presentation: This case report presents a 34-year-old woman suffered from metastases to the femur the lung and bilateral axillas from a malignant phyllodes tumor in 9 years. The most recent recurrence was discovered on bilateral axillas. The patient accepted adjuvant chemotherapy. However, because no obvious benefit of chemotherapy was found, the patient received bilateral axillary lymph node dissection finally. Genetic testing after surgery showed tumor-specific mutations and mutations about thepolymorphism of drug metabolism-related enzymes. Conclusions: The primary treatment modality for phyllodes tumor is surgery. For metastases, adjuvant chemotherapy may be efficient. However, when the effect of chemotherapy is not obvious, aggressive surgical therapies should be performed. Besides, genetic testing can provide advices on effective treatments.